Author

E. Mui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Assay:metabolomics· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Sinha· 2 shared C. A. Ford· 2 shared D. Sumpton· 2 shared E. Chang· 2 shared H. Y. Leung· 2 shared R. Patel· 2 shared S. Sinha· 2 shared A. Bispo· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Sinha

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Stretching the structural envelope of isomeric imatinib analogs that reduce β-amyloid production by modulating both β- and γ-secretase cleavages of APP

W. J. Netzer, A. Sinha, M. Ghias, E. Chang, K. Gindinova, E. Mui, J.-S. Seo, S. Sinha

The paper investigates how structurally diverse imatinib analogs affect APP metabolism similarly, identifying potent isomers for further development.

bioRxiv · Jul 14, 2024Pharmacology & Toxicology

Rational development of a small-molecule activator of CK1γ2 that decreases C99 and beta-amyloid levels

V. H. Bustos, Y. K. Sunkari, A. Sinha, M. Pulina, A. Bispo, M. Hopkins, A. Lam, S. F. Kriegsman, E. Mui, E. Chang, A. Jedlicki, H. Rosenthal, M. Flajolet, P. Greengard, S. Sinha

This study identifies CK1γ2 as a therapeutic target for Alzheimer's disease by showing its activation reduces C99 and beta-amyloid levels through increased PS1-Ser367 phosphorylation.

bioRxiv · Apr 28, 2023Pharmacology & Toxicology

THEM6-mediated lipid remodelling sustains stress resistance in cancer

A. Blomme, C. Peter, E. Mui, G. Rodriguez Blanco, L. M. Mason, L. E. Jamieson, G. H. McGregor, S. Lilla, C. Ntala, R. Patel, M. Thiry, S. H. Kung, C. A. Ford, L. K. Rushworth, D. J. McGarry, , H. Y. Leung

This study identifies THEM6 as a marker of ADT resistance in prostate cancer, showing its role in lipid homeostasis and stress response, and highlights it as a potential therapeutic target.

bioRxiv · Apr 4, 2021Cancer Biology

Cyclocreatine suppresses prostate tumorigenesis through dual effects on SAM and creatine metabolism

R. Patel, L. Rodgers, C. A. Ford, L. Rushworth, J. Fleming, E. Mui, T. Zhang, D. G. Watson, G. MacKay, D. Sumpton, O. J. Sansom, H. Y. Leung

This study identifies cyclocreatine as a dual-action inhibitor of prostate cancer by blocking the phosphagen system and increasing S-adenosyl methionine levels.

bioRxiv · Feb 26, 2021 · PreprintCancer Biology